Chemoradiotherapy, Adjuvant
"Chemoradiotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.
| Descriptor ID |
D059186
|
| MeSH Number(s) |
E02.186.079.500 E02.319.164.500 E02.815.160.500
|
| Concept/Terms |
Chemoradiotherapy, Adjuvant- Chemoradiotherapy, Adjuvant
- Adjuvant Chemoradiotherapies
- Chemoradiotherapies, Adjuvant
- Adjuvant Radiochemotherapy
- Adjuvant Radiochemotherapies
- Radiochemotherapies, Adjuvant
- Radiochemotherapy, Adjuvant
- Adjuvant Chemoradiotherapy
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemoradiotherapy, Adjuvant" by people in this website by year, and whether "Chemoradiotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoradiotherapy, Adjuvant" by people in Profiles.
-
Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. Int J Surg Pathol. 2021 Feb; 29(1):4-20.
-
Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer. Lung. 2018 06; 196(3):351-358.
-
Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation? J Clin Neurosci. 2017 Nov; 45:77-82.
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
-
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
-
Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Exp Mol Pathol. 2015 Jun; 98(3):338-45.
-
Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015 Jul 10; 33(20):2231-8.
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
-
Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
-
Radiotherapy for soft tissue sarcoma: 50 years of change and improvement. Am Soc Clin Oncol Educ Book. 2014; 244-51.